4basebio (LON:4BB) Announces Earnings Results

4basebio (LON:4BB) announced its earnings results on Wednesday. The company reported GBX (1.09) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The company had revenue of GBX 169 million during the quarter.

4basebio Stock Up 4.9%

Shares of 4basebio stock opened at GBX 509 on Friday. The business’s 50 day simple moving average is GBX 496.71 and its 200 day simple moving average is GBX 579.35. 4basebio has a 52-week low of GBX 420 and a 52-week high of GBX 1,150. The firm has a market cap of £78.82 million, a PE ratio of -5.14 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.